Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things clearly up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.
Presbyopia can be classified according to types incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia. It is mostly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible.
Presbyopia Epidemiology Segmentation in the 7MM
- Total Prevalent Cases of Presbyopia
- Total Diagnosed Cases of Presbyopia
- Total Age-Specific Cases of Presbyopia
- Gender-Specific Cases of Presbyopia
- Severity-Specific Cases of Presbyopia
Presbyopia Epidemiological Insights Observed in the 7MM (2021)
- The total number of incident cases of Presbyopia observed in the 7MM were observed to be 289 million in the year 2021
- The highest diagnosed Presbyopia population accounting for 118 million cases, was found in the United States in the year 2021, followed by EU5 (136 million cases) and Japan (34 million cases)
- The age-specific Presbyopia diagnosed cases observed in the United States were observed to be 28 million (less than 60 years), 33 million (60–69 years), 24 million (70–79 years), and 15 million (15 million) in the year 2021.
The market size of presbyopia in the 7MM was found to be approximately USD 17K Million in 2021.
Presbyopia Market Strengths
The aging population will significantly impact the number of people with Presbyopia. By 2032, the number of people worldwide aged 60 years and over is estimated to increase from million to billion, contributing to the presbyopia pool.
Presbyopia Market Opportunities
According to the WHO, 1.8 billion people (prevalence-25%) globally were diagnosed with presbyopia in 2015, with the prevalence rate expected to increase in the future. In the US alone, around 120 million people live with presbyopia. Increasing presbyopia cases will open a new window of opportunities for emerging therapies.
The emerging drugs in the Presbyopia market are
- MicroLine Pilocarpine Ophthalmic)
- CSF-1 (PresbiDrops)
- UNR844 (Lipoic Acid Choline Ester)
- VT-101 (Brimochol)
- LNZ100 (Aceclidine 1.75%)
- GLK-302 (Pilocarpine Ophthalmic Topical Cream)
- AGN-241622, and others
Presbyopia Key Players
The key players working in the Presbyopia market are
- Orasis Pharmaceuticals
- Ocuphire Pharma
- Visus Therapeutics
- LENZ Therapeutics
- Glaukos Corporation
- AbbVie, and others